A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This trial evaluates two standard of care treatments for opioid addiction: methadone and
buprenorphine/naloxone. In order to improve patient care, the study will address real-world
treatment conditions, including strict regulations for methadone dosing (i.e. initially
dispensed daily at the pharmacy until stabilisation) vs. flexible take-home dosing for
buprenorphine/naloxone. The OPTIMA study is designed with the intention to support
patient-provider decision-making and evaluate health related outcomes with the overall aim of
improving treatment outcomes through enhancing patient-centered approaches in clinical care.
Phase:
Phase 4
Details
Lead Sponsor:
Didier Jutras Aswad
Collaborator:
Canadian Institutes of Health Research (CIHR)
Treatments:
Analgesics, Opioid Buprenorphine Buprenorphine, Naloxone Drug Combination Methadone Naloxone